Biogem Istituto di Biologia e genetica molecolare

What Biogem Istituto di Biologia e genetica molecolare does

Biogem Istituto di Biologia e genetica molecolare is a private Italian biomedical research institute founded in 2005 in Ariano Irpino (Campania, Italy), structured as a consortium limited liability company (S.c.a r.l.). The institute conducts fundamental and translational research across two primary domains — molecular oncology (mesothelioma, melanoma, gastric cancer, hepatocellular carcinoma, glioblastoma) and translational nephrology (kidney disease, transplantation complications, microRNA biomarkers) — supported by a dedicated computational biology and bioinformatics laboratory. It operates a GLP-certified preclinical testing center (Centro di Saggio BPL) that delivers non-clinical safety studies, pharmacokinetics, biodistribution, analytical method development, and Xenograft/PDX oncological models, alongside fee-for-service biotechnology offerings including protein and antibody development, genetic diagnostics, cellular and animal model generation, and nutraceutical research support.

The institute generates revenue through a hybrid model combining competitive public grant funding (Italian Ministry of University and Research via FISA-2024, EU framework programs), project-based fee-for-service preclinical testing via its BiogemService.com commercial portal, and education-related income from the UIIP (University Industry Internship Program) ICT training academy. UIIP delivers 2-3 month SAP/Analytics/Web courses and has trained approximately 4,560 graduates over 26 years with a 95-98% placement rate into partner companies, anchored by Accenture and a network of 60+ national and multinational ICT firms. Biogem complements its scientific mission with cultural programming (the 'Le Due Culture' annual meeting hosting Nobel laureates, the Biogem Musica concert series, and the BIOGEO natural history museum), which functions as a reputational and stakeholder-engagement asset.

Recent strategic activity has tilted toward late-stage translational research and EU consortium leadership: the institute is the named coordinator of the European MOMENTUM project with 13 international partners and leads the MUR-funded ENACT project developing next-generation antibody-drug conjugates for treatment-resistant cancers in partnership with IRCCS IRST and Special Products Line. Co-authored research published in Nature Genetics established DNA methylation-based predictive models for immunotherapy outcomes in pleural mesothelioma. The institute maintains GLP certification, holds a granted patent on a laryngeal carcinoma biosensor, and has filed IP related to the ENACT ADC program. With 51-100 employees, no external venture or private equity backing, and no disclosed revenue, Biogem operates as a grant- and services-funded research entity whose growth is tied to competitive public funding cycles and the expansion of its EU consortium footprint.

Name

Biogem Istituto di Biologia e genetica molecolare

Legal name

Biogem S.c.a r.l.

Website

https://biogem.it

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Biogem is a private Italian biomedical research institute in Ariano Irpino conducting molecular oncology and nephrology research, operating a GLP-certified preclinical testing center, and running the UIIP ICT training program with Accenture and 60+ partner companies.

Ownership category

akta.pro rank

Product category

Biomedical Research and Preclinical Testing Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical Laboratories (621511), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA), Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Biomedical research services
• Preclinical GLP testing
• Molecular biology research
• Oncology research
• Biotechnological services

Headquarters

HQ city

Ariano Irpino

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Research Grants and Government Funding: Biogem receives funding from the Ministry of University and Research (MUR) for research projects such as the ENACT project financed under FISA-2024. The institute also participates in European research projects.
2. GLP Testing Services: The Centro di Saggio BPL (GLP Testing Center) provides fee-for-service preclinical testing including toxicity studies, pharmacokinetics, analytical method development, and oncological models to pharmaceutical companies.
3. Biotechnological Services: Fee-based services including protein and antibody development, genetic diagnostics, cellular and animal model development, and nutraceutical research support.
4. Training Programs (UIIP): The UIIP training program is free for selected participants, suggesting indirect revenue through corporate partnerships and placement fees from companies like Accenture.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Biogem is a private biomedical research institute providing GLP-certified preclinical testing services, biotechnological services (protein/antibody development, genetic diagnostics, cellular and animal models), and biomedical research in oncology and nephrology. It operates as a contract research organization serving pharmaceutical companies, universities, and research hospitals, supported by a biobank, bioinformatics capabilities, and a UIIP ICT training program.

Product overview

Biogem is a research institute offering a comprehensive portfolio of biomedical and biotechnological research services. Its core offerings include the Ricerca Biomedica division (oncology and nephrology research with computational biology capabilities), the Ricerca Biotecnologica service division (pharmacological development, protein/antibody production, genetic diagnostics), and the GLP-certified Centro di Saggio BPL (providing preclinical testing services including toxicity studies and oncological models). Supporting programs include the UIIP training program for ICT professionals and doctoral programs. Cultural initiatives encompass the Le 2ue Culture annual meeting and Biogem Musica concert series, alongside the BIOGEO museum.

Differentiator

Problem solved

Functional benefit

Brands

• BiogemService.com: GLP-certified testing center offering preclinical studies, toxicity studies, pharmacokinetics, and analytical method development services.
• UIIP
• Le Due Culture
• Biogem Musica
• Biogeo

Quantifiable outcome

• 98% placement rate for UIIP program graduates
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• IRCCS Istituto Romagnolo per lo Studio dei Tumori - IRST SrlcoreStrategic or Co-development Partner · 3 June 2026Collaborative partner in the ENACT project for developing novel antibody-drug conjugates for cancer therapeutics. IRST contributes clinical expertise and patient access for the research program.
• Special Products Line (Azienda Farmaceutica) - AnagnicoreStrategic or Co-development Partner · 3 June 2026Pharmaceutical company partner in the ENACT project contributing pharmaceutical development expertise and potential commercialization pathways for new ADC therapeutics.
• Università degli Studi di SienacoreStrategic or Co-development PartnerAcademic research partner in the NIBIT-EPI-MESO study on DNA methylation and immunotherapy outcomes in pleural mesothelioma, contributing molecular biology expertise.
• Università degli Studi di FerraracoreStrategic or Co-development PartnerAcademic partner in mesothelioma research collaborating on the international study published in Nature Genetics on DNA methylation subtypes predicting immunotherapy outcomes.
• AccenturecoreChannel Partner/ Reseller/ DistributorMain sponsor of the UIIP SAP Consultant Academy training program. Provides placement opportunities for graduates completing the 10-week training program at Biogem campus. Primary destination for program graduates.
• 60+ ICT Companies (UIIP Network)minorChannel Partner/ Reseller/ DistributorNetwork of national and multinational ICT companies partnering with Biogem's UIIP training program for graduate recruitment, including Sopra Steria Group and other enterprise IT firms.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Charles River Laboratories: Global preclinical CRO offering GLP toxicology, PK/biodistribution, and oncology models — directly overlaps Biogem's Centro di Saggio BPL services but at vastly greater scale, serving as the benchmark incumbent for Biogem's CRO business.
• Eurofins Scientific: International bioanalytical and laboratory testing group with a significant Italian footprint; competes with BiogemService on bioanalytical method development, PK assays, and specialty lab services.
• Evotec SE: European drug discovery and preclinical services platform with integrated computational biology; comparable to Biogem's combination of GLP testing, biotech services, and bioinformatics-led discovery.
• Syneos Health: Global clinical and preclinical CRO serving pharma and biotech across preclinical and clinical development — represents the scale of integrated service provider Biogem could only aspire to with significant capital.
• Labcorp Drug Development: Global central lab and early development CRO offering GLP bioanalytical, PK, and biomarker services that directly overlap Biogem's GLP testing center and DNA methylation biomarker work.

Direct peers

• IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST): Italian cancer research hospital and named Biogem partner in both the ENACT ADC project and the NIBIT-EPI-MESO immunotherapy study; operates an analogous translational research plus clinical oncology model.
• IFOM (FIRC Institute of Molecular Oncology): Milan-based Italian molecular oncology research institute combining basic biology, translational research, and technology platforms — the closest domestic analogue to Biogem's biomedical research + biotechnology services hybrid.
• TIGEM (Telethon Institute of Genetics and Medicine): Pozzuoli-based Italian genetics and molecular medicine research institute with similar public-grant funding model, biotech services, and drug discovery programs targeted at rare and genetic diseases.
• Istituto Italiano di Tecnologia (IIT): Italian government-funded research foundation operating across robotics, life sciences, and computational biology with a translational mandate — comparable mission structure and grant dependency, though on a much larger scale.

Regional players

• Sanofi Genzyme Polyclonal Antibody Services / Biotest AG: European protein and antibody development service providers comparable to Biogem's Ricerca Biotecnologica protein/antibody production and genetic diagnostics offerings, though operating at commercial manufacturing scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/biogem_istituto
• YouTubeyoutube.com/channel/UC9ixxtJPRoreaXgU99ZpJ6w
• Facebookfacebook.com/biogem.it
• LinkedInlinkedin.com/company/biogem-istituto-di-ricerche-genetiche-gaetano-salvatore
• Instagraminstagram.com/biogemistituto/?hl=it

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biogem Istituto di Biologia e genetica molecolare